Cargando…

Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease

With the increasing incidence and prevalence, Crohn’s disease (CD) has become one of the most challenging diseases in both diagnosis and treatment of gastroenterology. Evaluation of the disease activity and mucosal healing guides clinical decisions regarding subsequent therapy for CD. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zhou, Zhang, Yinghui, Yang, Xue, Pan, Yan, Li, Liangping, Gao, Caiping, He, Chong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931310/
https://www.ncbi.nlm.nih.gov/pubmed/35309310
http://dx.doi.org/10.3389/fimmu.2022.865968
_version_ 1784671230569218048
author Zhou, Zhou
Zhang, Yinghui
Yang, Xue
Pan, Yan
Li, Liangping
Gao, Caiping
He, Chong
author_facet Zhou, Zhou
Zhang, Yinghui
Yang, Xue
Pan, Yan
Li, Liangping
Gao, Caiping
He, Chong
author_sort Zhou, Zhou
collection PubMed
description With the increasing incidence and prevalence, Crohn’s disease (CD) has become one of the most challenging diseases in both diagnosis and treatment of gastroenterology. Evaluation of the disease activity and mucosal healing guides clinical decisions regarding subsequent therapy for CD. In this study, we enrolled a total of 144 patients with CD and 239 healthy controls were enrolled. Clinical characteristics and laboratory parameters of enrolled subjects were retrieved from the electronic medical record database of our hospital. Serum cytokine levels were measured by enzyme-linked immunosorbent assay (ELISA). Mucosa expression levels of inflammatory agents were measured by quantitative RT-PCR (qRT-PCR). We identified two neutrophil-based indexes, the neutrophil-to-albumin ratio (NAR) and neutrophil-to-bilirubin ratio (NBR), both of which had not yet been explored in CD or UC. NAR and NBR were significantly increased in patients with CD compared to those in healthy controls, and both indexes showed significantly positive correlations with CD activity and inflammatory load. In note, NAR and NBR showed better performance than blood neutrophil percentage, serum albumin, or bilirubin alone in these scenarios. More importantly, both NAR and NBR discriminated CD patients who completely or partially responded to infliximab (IFX) induction therapy from those with primary non-response. Our observations suggest that NAR and NBR may serve as promising biomarkers in the diagnosis and prediction of response to IFX therapy in CD.
format Online
Article
Text
id pubmed-8931310
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89313102022-03-19 Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease Zhou, Zhou Zhang, Yinghui Yang, Xue Pan, Yan Li, Liangping Gao, Caiping He, Chong Front Immunol Immunology With the increasing incidence and prevalence, Crohn’s disease (CD) has become one of the most challenging diseases in both diagnosis and treatment of gastroenterology. Evaluation of the disease activity and mucosal healing guides clinical decisions regarding subsequent therapy for CD. In this study, we enrolled a total of 144 patients with CD and 239 healthy controls were enrolled. Clinical characteristics and laboratory parameters of enrolled subjects were retrieved from the electronic medical record database of our hospital. Serum cytokine levels were measured by enzyme-linked immunosorbent assay (ELISA). Mucosa expression levels of inflammatory agents were measured by quantitative RT-PCR (qRT-PCR). We identified two neutrophil-based indexes, the neutrophil-to-albumin ratio (NAR) and neutrophil-to-bilirubin ratio (NBR), both of which had not yet been explored in CD or UC. NAR and NBR were significantly increased in patients with CD compared to those in healthy controls, and both indexes showed significantly positive correlations with CD activity and inflammatory load. In note, NAR and NBR showed better performance than blood neutrophil percentage, serum albumin, or bilirubin alone in these scenarios. More importantly, both NAR and NBR discriminated CD patients who completely or partially responded to infliximab (IFX) induction therapy from those with primary non-response. Our observations suggest that NAR and NBR may serve as promising biomarkers in the diagnosis and prediction of response to IFX therapy in CD. Frontiers Media S.A. 2022-03-04 /pmc/articles/PMC8931310/ /pubmed/35309310 http://dx.doi.org/10.3389/fimmu.2022.865968 Text en Copyright © 2022 Zhou, Zhang, Yang, Pan, Li, Gao and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhou, Zhou
Zhang, Yinghui
Yang, Xue
Pan, Yan
Li, Liangping
Gao, Caiping
He, Chong
Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease
title Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease
title_full Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease
title_fullStr Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease
title_full_unstemmed Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease
title_short Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease
title_sort clinical significance of novel neutrophil-based biomarkers in the diagnosis and prediction of response to infliximab therapy in crohn’s disease
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931310/
https://www.ncbi.nlm.nih.gov/pubmed/35309310
http://dx.doi.org/10.3389/fimmu.2022.865968
work_keys_str_mv AT zhouzhou clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease
AT zhangyinghui clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease
AT yangxue clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease
AT panyan clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease
AT liliangping clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease
AT gaocaiping clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease
AT hechong clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease